Evidence map›Paper›PMID 35475723›Full record

ArticleClinical chemistry and laboratory medicine2022

Patients with severe COVID-19 do not have elevated autoantibodies against common diagnostic autoantigens.

Antigona Ulndreaj, Mingyue Wang, Salvia Misaghian, Louis Paone, George B Sigal, Martin Stengelin, Christopher Campbell, Logan R Van Nynatten, Antoninus Soosaipillai, Atefeh Ghorbani and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical chemistry and laboratory medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Antigona UlndreajLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.ORCID 0000-0003-1650-1187
Mingyue WangMeso Scale Diagnostics, LLC. (MSD), Rockville, MD, USA.
Salvia MisaghianMeso Scale Diagnostics, LLC. (MSD), Rockville, MD, USA.
Louis PaoneMeso Scale Diagnostics, LLC. (MSD), Rockville, MD, USA.
George B SigalMeso Scale Diagnostics, LLC. (MSD), Rockville, MD, USA.
Martin StengelinMeso Scale Diagnostics, LLC. (MSD), Rockville, MD, USA.
Christopher CampbellMeso Scale Diagnostics, LLC. (MSD), Rockville, MD, USA.
Logan R Van NynattenLawson Health Research Institute, London, ON, Canada.
Antoninus SoosaipillaiDepartment of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada.
Atefeh GhorbaniDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Anu MathewMeso Scale Diagnostics, LLC. (MSD), Rockville, MD, USA.
Douglas D FraserLawson Health Research Institute, London, ON, Canada.
Eleftherios P DiamandisLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.ORCID 0000-0002-1589-820X
Ioannis PrassasLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
Meso Scale Discovery (United States) · USMount Sinai Hospital · CAWestern University · CAUniversity of Toronto · CA

Funding

Highly Sensitive and Specific MSD Multiplexed Autoimmune Disease PanelU24AI118660 · NIAID · MESO SCALE DIAGNOSTICS, LLC · PI MATHEW, ANU · 2015 to 2019
$1.9M
NIAID NIH HHS U24 AI118660
6 · The paper itself

Abstract

objectivesInfection by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19) presents occasionally with an aberrant autoinflammatory response, including the presence of elevated circulating autoantibodies in some individuals. Whether the development of autoantibodies against self-antigens affects COVID-19 outcomes remains unclear. To better understand the prognostic role of autoantibodies in COVID-19, we quantified autoantibodies against 23 markers that are used for diagnosis of autoimmune disease. To this end, we used serum samples from patients with severe [intensive care unit (ICU)] and moderate (ward) COVID-19, across two to six consecutive time points, and compared autoantibody levels to uninfected healthy and ICU controls.

methodsAcute and post-acute serum (from 1 to 26 ICU days) was collected from 18 ICU COVID-19-positive patients at three to six time points; 18 ICU COVID-19-negative patients (sampled on ICU day 1 and 3); 21 ward COVID-19-positive patients (sampled on hospital day 1 and 3); and from 59 healthy uninfected controls deriving from two cohorts. Levels of IgG autoantibodies against 23 autoantigens, commonly used for autoimmune disease diagnosis, were measured in serum samples using MSD

resultsThere were no significant elevations of autoantibodies for any of the markers tested in patients with severe COVID-19.

conclusionsSample collections at longer time points should be considered in future studies, for assessing the possible development of autoantibody responses following infection with SARS-CoV-2.

Indexed as

Autoimmune DiseasesCOVID-19AutoantibodiesAutoantigensHumansSARS-CoV-2AutoantibodiesAutoantigensautoantibodiesautoimmunityCOVID-19electrochemiluminescenceIntensive care unit (ICU)prognostic markersSARS-CoV-2severe disease

Identifiers

PMID35475723
PMCPMC9128368
OpenAlexW4224996503

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.